



Press release

EVERZOM Enters Research Collaboration with GENFIT Including Exclusive License Option for EViv, Its Exosome-Based Investigational Drug Candidate in Acute Liver Diseases

This agreement supports EVERZOM's dynamic development strategy and follows the recent announcement of a €10M financing round aimed at accelerating its clinical and partnering roadmap.

Strasbourg, November 10, 2025 – EVERZOM, a French biotechnology company pioneering exosome-based therapies for regenerative medicine applications, today announced the signing of a first research partnership with GENFIT, a biopharmaceutical company specializing in rare liver diseases. The collaboration aims to evaluate EViv, EVERZOM's second proprietary investigational drug candidate, developed to treat Acute-on-Chronic Liver Failure (ACLF). Pending positive in vivo proof-of-concept results, GENFIT will have the option to exercise an exclusive license in the field of acute liver diseases.

ACLF is a severe hepatic syndrome characterized by an acute decompensation occurring in a chronically injured liver, leading to explosive systemic inflammation, multiple organ failure, high short-term mortality, and significant unmet clinical need. Apart from liver transplantation, current therapeutic options remain limited and insufficient, underscoring the urgency of new regenerative approaches.

Under the terms of the agreement, EVERZOM will provide its proprietary technological expertise in exosomes and their immunomodulatory properties, as well as access to its exosome bioproduction platform. GENFIT will oversee the preclinical evaluation of EViv, with a clear go/no-go decision point within 18 months regarding potential progression into clinical development.

"This first research partnership for EViv marks an important milestone in EVERZOM's strategy: demonstrating the clinical versatility of exosomes in regenerative medicine across indications with significant unmet need, such as hepatology, dermatology, and ophthalmology. GENFIT is an ideal partner to accelerate proof-of-concept and prepare clinical access in ACLF," said **Jeanne Volatron, Co-Founder and CEO of EVERZOM.**

"This collaboration demonstrates the ability of EVERZOM to transform its scientific excellence into industrial momentum and work with leading partners. It also strengthens the company's positioning in the regenerative therapies market," added **Michel Finance, Chairman of EVERZOM's Board of Directors.**

EViv: a therapeutic candidate for severe liver diseases

EViv is an intravenous exosome formulation designed to act systemically on acute inflammatory storms by reducing pro-inflammatory cytokines (TNF- α , IL-1 β), stimulating anti-inflammatory pathways (IL-10, IDO-1), shifting macrophages toward an M2 profile, and limiting tissue damage through the transfer of reparative microRNAs and proteins. This approach positions EViv as a global inflammation modulator and promoter of tissue regeneration.



Exosomes: a promising new therapeutic modality

In mid-October, EVerZom announced a €10M financing round from leading European investors. These funds will enable the launch in 2026 of the first clinical study for **EverGel™**, the company's lead investigational drug for complex perianal fistulas in Crohn's disease, while reinforcing the industrial capacity of its GMP-grade manufacturing platform and expanding exosome applications into new indications.

Exosomes are biological nanoparticles secreted by cells and increasingly recognized as therapeutic intercellular messengers capable of transporting functional proteins, mRNA, and microRNA. Compared to cellular therapies, they offer enhanced stability, reduced variability of clinical outcomes, strengthened clinical safety, and simplified logistics (including immediate hospital storage).

Press contact: Florence Portejoie, **FP2COM** — +33 6 07 76 82 83 — fportejoie@fp2com.fr

About EVerZom

EVerZom is a French biotechnology company pioneering next-generation regenerative therapies leveraging exosomes derived from mesenchymal stem cells. Its proprietary bioproduction platform enables high-yield, GMP-compliant exosome manufacturing and innovative formulation approaches combining exosomes with biomaterials to enhance therapeutic efficacy and durability.

In October 2025, EVerZom raised €10M from leading European investors—including Capital Grand Est, the EIC Fund, Sorbonne Venture, and others—to accelerate its clinical and industrial strategy. The company's lead candidate, **EverGel™**, targets complex perianal fistulas in Crohn's disease, with first-in-human trials expected in 2026. Its second program, **EViv**, focuses on Acute-on-Chronic Liver Failure (ACLF). Founded in 2019, EVerZom is a laureate of the EIC Accelerator and a recipient of France 2030 support, positioning it as a European leader in exosome-based regenerative medicine.

For more information: <https://everzom.com>